Abstract

ObjectivesGO-SAVE is a Ph3b, multi-center, switch assessment of SC and IV golimumab (GLM) in RA pts who have inadequate disease control despite treatment with etanercept (ETN) or adalimumab (ADA). Primary...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call